Other formats:
BibTeX
LaTeX
RIS
@article{1159351, author = {Češková, Eva}, article_number = {2}, keywords = {Evidence-based medicine; Individualized medicine; Schizophrenia}, language = {eng}, issn = {0391-1772}, journal = {Minerva Psichiatrica}, title = {Practical issues in the treatment of schizophrenia}, url = {http://www.scopus.com/record/display.url?eid=2-s2.0-84882412314&origin=resultslist&sort=plf-f&src=s&st1=0391-1772&sid=BE8C6718AF3187DA5FA1E89C09808815.kqQeWtawXauCyC8ghhRGJg%3a620&sot=b&sdt=b&sl=15&s=ISSN%280391-1772%29&relpos=1&relpos=1&citeCnt=0&search}, volume = {54}, year = {2013} }
TY - JOUR ID - 1159351 AU - Češková, Eva PY - 2013 TI - Practical issues in the treatment of schizophrenia JF - Minerva Psichiatrica VL - 54 IS - 2 SP - 101-113 EP - 101-113 PB - Edizioni Minerva Medica S.p.A. SN - 03911772 KW - Evidence-based medicine KW - Individualized medicine KW - Schizophrenia UR - http://www.scopus.com/record/display.url?eid=2-s2.0-84882412314&origin=resultslist&sort=plf-f&src=s&st1=0391-1772&sid=BE8C6718AF3187DA5FA1E89C09808815.kqQeWtawXauCyC8ghhRGJg%3a620&sot=b&sdt=b&sl=15&s=ISSN%280391-1772%29&relpos=1&relpos=1&citeCnt=0&search L2 - http://www.scopus.com/record/display.url?eid=2-s2.0-84882412314&origin=resultslist&sort=plf-f&src=s&st1=0391-1772&sid=BE8C6718AF3187DA5FA1E89C09808815.kqQeWtawXauCyC8ghhRGJg%3a620&sot=b&sdt=b&sl=15&s=ISSN%280391-1772%29&relpos=1&relpos=1&citeCnt=0&search N2 - Treatment should be evidence-based, measurement-based, complex (including pharmacotherapy, psychosocial intervention, and physical health care) and individualized (tailored to the patient). The basis of schizophrenia treatment is still pharmacotherapy. The first generation of antipsychotics (FGAs), known as typical APs, was discovered in the 1950s. Most second generation antipsychotics (SGAs), known as atypical APs, have been developed more recently. SGAs present some advantages in the treatment of certain treatment domains. The binding affinity of APs for specific neuroreceptors is associated with the therapeutic effect, but also with adverse events. The choice of AP for the individual patient should be guided by the side effect profile of the drug, patient experience with certain side effects, previous patient response to certain APs (e.g., individualized treatment), and potential interactions with other prescribed medication. There are some special clinical features influencing the choice of AP treatment (negative, cognitive, depressive and catatonic symptoms, agitation, non-adherence, pharmacoresistance). These features are discussed in more details. In the future more targeted therapies will be available, offering and enhance efficacy and hopefully also safety. ER -
ČEŠKOVÁ, Eva. Practical issues in the treatment of schizophrenia. \textit{Minerva Psichiatrica}. Edizioni Minerva Medica S.p.A., 2013, vol.~54, No~2, p.~101-113. ISSN~0391-1772.
|